CTLA4 and neoplasm: The combination of metformin with anti-CTLA-4 (clone 9D9) showed a substantial improvement in tumor shrinkage and cytotoxic T lymphocyte activity in 4T1 breast cancer, B16F10 melanoma, and CT26 colon cancer without significant body weight changes or observable damage in the kidneys or liver [156].